Revenue rises 10.9% yoy to RM128.6 million driven by rising patient loads and average bill sizes. The Group’s latest investment, StarMed Specialist Centre, has begun operations with corresponding gestation start-up costs. Excluding the impact from StarMed, EBITDA would have increased 4.9% yoy while core PATMI would have increased 15.5% yoy. Declares an interim dividend of RM1.0 cents per share (1H2018: RM1.0 cents per share)…
